Clinical Trials
12 trialsNCT07612098 2026-05-28
SPARE-04
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07381309 2026-04-28
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07549399 2026-04-24
CRITâ…¡
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07318636 2026-01-06
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 1 Not yet recruiting
NCT07277842 2025-12-11
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07245901 2025-11-24
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT07053150 2025-07-08
CCGLC-018
Tongji Hospital
Phase 2 Not yet recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06665087 2024-10-30
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
Fudan University
Phase 2 Not yet recruiting
NCT06647563 2024-10-18
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT06364787 2024-04-15
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Beijing 302 Hospital
Phase 1 Not yet recruiting
NCT06364800 2024-04-15
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Beijing 302 Hospital
Phase EARLY_PHASE1 Not yet recruiting